Crinetics Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- R. Scott Struthers
- Full Time Employees
- 437
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building No. 2 San Diego CA United States of America 92121
- IPO Date
- Jul 18, 2018
- CIK
- 0001658247
- Website
- crinetics.com
- Similar Companies
- Business
- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) develops novel oral small-molecule therapeutics for rare endocrine diseases and endocrine-related tumors; its approved lead product PALSONIFY (paltusotine), a once-daily selective somatostatin receptor type 2 (SST2) nonpeptide agonist, treats adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option, while also advancing in Phase 3 for carcinoid syndrome associated with neuroendocrine tumors (NETs); late-stage pipeline includes atumelnant (CRN04894), an oral melanocortin type 2 receptor (MC2R) antagonist in Phase 2/3 for classic congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome; CRN09682, a first-in-class nonpeptide drug conjugate (NDC) delivering monomethyl auristatin E (MMAE) to SST2-expressing tumors including NETs and other solid tumors, with Phase 1/2 dosing initiated in December 2025; early-stage candidates in IND-enabling studies comprise a TSH antagonist for Graves’ hyperthyroidism and orbitopathy (thyroid eye disease), SST3 agonist for autosomal dominant polycystic kidney disease (ADPKD), and PTH antagonist for hyperparathyroidism. Founded in 2008 by Scott Struthers and colleagues with endocrinology expertise from Neurocrine Biosciences, the company is headquartered in San Diego, California, with an additional office in Zug, Switzerland, and operates globally with a focus on GPCR-targeted therapies discovered in-house. Recent developments include FDA approval of paltusotine in 2025 with commercialization underway, first patient dosing in the CRN09682 Phase 1/2 trial in December 2025 marking a milestone for its NDC platform, first patient randomization in the pivotal Phase 3 CAREFNDR trial for paltusotine in carcinoid syndrome, a $350 million oversubscribed private placement in early 2024 to fund R&D and operations, and a partnership with Sanwa Kagaku Kenkyusho for paltusotine commercialization in Japan.
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy' Initiative to Empower People Across Endocrine Disease Communities
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
Crinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?
Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
Jeff Knight Sells 85,163 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Analysts
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
Crinetics Pharmaceuticals Highlights Early PALSONIFY Sales, EU Milestone, and GPCR Pipeline at TD Cowen Conf.
Intech Investment Management LLC Has $926,000 Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript